EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study

Jason Valent, Jeffrey Zonder, E Scott Swenson, Julia Catini, Richa Manwani, Bhavna Ahuja, Zilehuma Khan, Michaela Liedtke

European Journal of Cancer · 2026-11 · 248 · 117039

DOI: 10.1016/j.ejca.2026.117039 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von Jason Valent und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Immunoglobulin Light-chain Amyloidosis. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Alexion Pharmaceuticals Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalImmunoglobulin Light-chain AmyloidosisAgedAged, 80 and overFemaleHumansMaleMiddle AgedImmunoglobulin Light Chains

Stichwörter der Autor:innen

Anselamimab (CAEL-101)Antifibril therapyCardiac responseLight chain (AL) amyloidosisRenal response

Substanzen

Antibodies, MonoclonalImmunoglobulin Light Chains

Autor:innen und Institutionen

  • Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
  • Clinical Development, Alexion, AstraZeneca Rare Disease, New Haven, CT, USA.
  • Global Medical Affairs, Alexion, AstraZeneca Rare Disease, Wilmington, DE, USA.
  • Clinical Development, Alexion, AstraZeneca Rare Disease, London, UK.
  • Fortrea, Inc., Durham, NC, USA.

Förderung

  • Alexion Pharmaceuticals Inc

Zitieren

APA

Valent, J., Zonder, J., Swenson, E. S., Catini, J., Manwani, R., Ahuja, B., Khan, Z., & Liedtke, M. (2026). Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study. European Journal of Cancer, 248, 117039. https://doi.org/10.1016/j.ejca.2026.117039

Vancouver

Valent J, Zonder J, Swenson ES, Catini J, Manwani R, Ahuja B, et al. Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study. European Journal of Cancer. 2026;248:117039. doi:10.1016/j.ejca.2026.117039

BibTeX
@article{Valent2026,
  author = {Valent, Jason and Zonder, Jeffrey and Swenson, E Scott and Catini, Julia and Manwani, Richa and Ahuja, Bhavna and Khan, Zilehuma and Liedtke, Michaela},
  title = {Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {248},
  pages = {117039},
  doi = {10.1016/j.ejca.2026.117039}
}
Kostenlos starten →